GTx and Oncternal Therapeutics today disclosed plans for a reverse merger that would create a combined company specializing in clinical and preclinical oncology treatments. Under the reverse merger, whose value was not disclosed, Oncternal shareholders will own the majority of shares in the combined company, also to be named Oncternal Therapeutics. In entering into the merger, […]
The post Cancer Drug Developers GTx, Oncternal Plan Reverse Merger appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Cancer Drug Developers GTx, Oncternal Plan Reverse Merger